Objective: Prevailing theory and research suggests the psychological and physiological discomfort associated with tobacco withdrawal may play a formative role in the risk of cessation failure. Yet, research elucidating cognitive-affective vulnerability characteristics that contribute to increased tobacco withdrawal severity during periods of planned abstinence is highly limited. In the current study, we explored whether smokers with greater reductions of Anxiety Sensitivity (AS) and dysphoria during a smoking cessation intervention would experience less severe postquit tobacco withdrawal. Method: Specifically, the interactive effect of change (from preintervention baseline to quit day) in AS and dysphoria in relation to postquit withdrawal severity (quit day through 12 weeks postquit) was examined among treatment-seeking adult smokers enrolled in a smoking cessation trial (N ϭ 198; 55.3% female; 86.8% Caucasian; M age ϭ 38.8, SD ϭ 14.0). Results: Results indicated that the interactive effect of change in AS and dysphoria was related to linear change in postquit withdrawal symptoms. Specifically, larger reductions in AS were associated with a faster decline in the severity of withdrawal symptoms across the 12-week postquit period only for individuals with lower (but not higher) reductions in dysphoria. Additionally, the findings indicated that reducing levels of AS and dysphoria prequit is broadly related to the degree of change in postquit withdrawal symptoms. Conclusion: Collectively, these data suggest there is apt to be clinical merit to employing strategies to address AS and/or dysphoria to more effectively manage emergent withdrawal symptoms following smoking cessation treatment.
What is the public health significance of this article?
The current study offers novel insight into the clinically important role of anxiety sensitivity and dysphoria in relation to tobacco withdrawal. The benefits of a pre-quit reduction in AS in terms of the severity of withdrawal was seen most prominent for smokers with lower pre-quit dysphoria. Specifically, reducing levels of AS and dysphoria pre-quit is broadly related to the degree of change in post quit withdrawal symptoms.
Keywords: anxiety sensitivity, dysphoria, smoking cessation, tobacco withdrawal Tobacco withdrawal represents a constellation of affective, cognitive, and somatic features that onset upon the discontinuation of chronic smoking because of the expression of nicotine-induced neuroadaptations and loss of the smoking ritual (Baker et al., 2007) . Withdrawal is a key marker of tobacco dependence and is likely a major contributor to smoking relapse (Baker et al., 2007) . Empirical data supports a robust association between withdrawal symptom severity and quit success (Piasecki, 2006; Piasecki et al., 2000) .
A wide range of cognitive-affective factors (e.g., emotional states, clinical syndromes, or cognitive styles) have been implicated in tobacco withdrawal (Abrantes et al., 2008; Leventhal, Waters, Boyd, Moolchan, Heishman et al., 2007; . This work broadly suggests individual differences in cognitive-affective vulnerabilities can increase the risk of more severe withdrawal (Covey, 1999) . As one illustrative example, nonclinical anhedonia symptoms are associated with more severe tobacco withdrawal (Langdon et al., 2013) . Such work suggests identifying distinct (cognitive-affective) processes that govern withdrawal is a key, clinically relevant, question to address for smokers in general, and those with cognitive-affective vulnerabilities specifically.
One promising cognitive-affective construct to better understand tobacco withdrawal is Anxiety Sensitivity (AS). AS reflects the tendency to fear of anxiety-related sensations arising from beliefs that these sensations have harmful psychological, social, and somatic consequences (Reiss & McNally, 1985) . AS is a relatively stable, but malleable, construct involved in the etiology and maintenance of anxiety and depressive disorders (Otto et al., 2016) . Smokers with increased AS perceive quitting as more difficult (Johnson, Farris, Schmidt, Smits, & Zvolensky, 2013) and are more motivated to smoke to reduce negative affect (Battista et al., 2008) . Furthermore, AS explains the relation of emotional disorders with numerous clinical indicators of smoking severity, such as cigarette dependence (Zvolensky, Farris, Leventhal, & Schmidt, 2014) . Past work suggests smokers with greater AS experience more severe tobacco withdrawal during periods of smoking abstinence (Zvolensky, Farris, Guillot, & Leventhal, 2014) as well as greater risk of early lapse (Brown, Kahler, Zvolensky, Lejuez, & Ramsey, 2001 ) and relapse (Assayag, Bernstein, Zvolensky, Steeves, & Stewart, 2012) .
As a malleable construct, AS can change in response to life events (e.g., stress exposure; Marshall, Miles, & Stewart, 2010) , and be reduced via specialized (i.e., AS-specific) and nonspecialized interventions (i.e., cognitive-behavioral stress management; Ablon, Levy, & Katzenstein, 2006; McHugh et al., 2014 : Schmidt et al., 2007 . Moreover, AS can be reduced via targeted, brief (e.g., less than 60-min) interventions (Keough, & Schmidt, 2012; Smits, Berry, Tart, & Powers, 2008) , and such change in AS mediates improvement in anxiety/depressive symptoms (Schmidt, Capron, Raines, & Allan, 2014; Timpano, Raines, Shaw, Keough, & Schmidt, 2016) . Furthermore, smoking treatments that focus on reducing AS prior to quitting yield better rates of smoking abstinence (Zvolensky, Bogiaizian, Salazar, Farris, & Bakhshaie, 2014) . Specifically, prequit reductions in AS decrease the odds of early cessation failure (Smits et al., 2016 ). Yet, a central gap in the AS-smoking literature is whether change in AS prior to a quit attempt is related to distinct tobacco withdrawal trajectories. Because AS serves as an affect amplifier (Zvolensky, Bogiaizian et al., 2014) , it would be expected that decreased AS prior to quitting would be related to less postquit severe tobacco withdrawal .
Theoretical models of smoking-affect associations predict that AS is likely to interplay with other affect processes in predicting smoking behavior generally, and tobacco withdrawal specifically . Dysphoria, representing depressive symptoms characterized by intense unhappiness and discontent, may be one such common candidate (Cella, Cooper, Dymond, & Reed, 2008; Starcevic, 2007) . Past work has found that dysphoria is associated with numerous aspects of smoking behavior, including greater dependence, higher smoking rates, and more negative affect reduction smoking motives (Leventhal, Zvolensky, & Schmidt, 2011) , as well as more perceived barriers to cessation (Buckner et al., 2015) . Moreover, greater levels of dysphoria are associated with more severe and protracted withdrawal symptoms (Covey, Glassman, & Stetner, 1990; Hall, Muñoz, Reus, & Sees, 1993) . Dysphoria also can increase in response to life stress (Beevers, & Carver, 2003) and be reduced via specialized (Dobkin, Panzarella, Fernandez, Alloy, & Cascardi, 2004; Seligman, Steen, Park, & Peterson, 2005) and nonspecialized (Reinecke, Ryan, & DuBois, 1998) interventions. Other work suggests reductions in dysphoria are related to better psychological and addictive behavior outcomes (Ginsberg, Hall, Reus, & Muñoz, 1995) . Thus, while dysphoria would be expected to be related to more severe tobacco withdrawal, it has not been frequently studied within the context of other variables, such as AS.
One key clinically relevant question that has thus far been unexamined is whether change in AS or dysphoria singularly or interactively is related to distinct tobacco withdrawal trajectories. Theoretically, AS and dysphoria may act on tobacco withdrawal in distinct ways, although there is limited work to date on this topic. One study found that the interaction of AS and anhedonia (a facet of dysphoria) at study entry predicted more severe postquit withdrawal symptoms during smoking cessation treatment (Langdon et This document is copyrighted by the American Psychological Association or one of its allied publishers.
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al., 2013). The nature of this association was such that the prequit levels of elevated AS and anhedonia predicted greater withdrawal. Other work has identified an interactive effect for AS and dysphoria in terms of smoking-related emotion regulatory cognition (Garey et al., 2016) . Interestingly, the nature of the interactive effect suggested dysphoria may mitigate the effects of AS for smoking processes. Specifically, the effect of AS for smoking variables may be "blunted" when dysphoria is high (Garey et al., 2016) . Theoretically, these data suggest the emotional inertia (commonly associated with dysphoria; Brose, Schmiedek, Koval, & Kuppens, 2015) may diminish the role of AS in terms of (certain) smoking processes. Specifically, dysphoric symptoms may be such a robust predictor of smoking that concomitant AS does not further impact such outcomes. At lower levels of dysphoria, however, the effects of AS on smoking processes are more apt to be evident (Garey et al., 2016) . Although there has been promise thus far in exploring how AS and dysphoria interplay in certain aspects of smoking behavior, past work has yet to explore the nature of prequit change in these constructs in relation to tobacco withdrawal. It is important to elucidate the interactive nature of change in these constructs in terms of withdrawal because such work will directly inform therapeutic processes during smoking cessation treatment (Chua et al., 2011; . An important next research step therefore is to examine how prequit changes in AS and dysphoria as well as their interaction influence withdrawal symptom severity. Specifically, such work will enhance understanding of the malleability of AS and dysphoria and their role as targetable risk factors in the context of smoking cessation treatment. Consistent with research documenting that dysphoric symptoms may be risk factor for emotionally laden tobacco withdrawal (Breslau, Kilbey, & Andreski, 1992; Garey et al., 2016; Pomerleau, Marks, & Pomerleau, 2000) , the effects of change in AS would be expected to be evident in instances wherein change in dysphoria is minimal.
Together, the current study examined the effects of change (from preintervention baseline to quit day) in AS and dysphoria in relation to postquit withdrawal severity among adult smokers enrolled in a smoking cessation trial (Schmidt, Raines, Allan, & Zvolensky, 2016) . Drawing from past work (Garey et al., 2016) , it was hypothesized that change in dysphoria prior to quit attempt would moderate the effects of the prequit change in AS for withdrawal symptoms. Specifically, smokers would benefit the most from the reduction in AS when they experience lower levels of dysphoria.
Method Participants
Participants were smokers enrolled in a clinical trial evaluating the efficacy of a transdiagnostic smoking cessation treatment relative to a standard smoking cessation treatment . Eligibility criteria for the trial included: (a) 18 -65 years of age; (b) being a daily smoker for at least 1 year; (c) currently smoking a minimum of eight cigarettes per day; and (d) motivation to quit smoking. Exclusion criteria for the trial included: (a) current use of pharmacotherapy for smoking cessation (except the nicotine patch, which was provided by the study); (b) limited mental competency and inability to provide informed, voluntary, written consent; (c) endorsement of current or past psychoticspectrum symptoms; (d) current suicidality or homicidality; (e) history of significant medical condition; and (f) planning to relocate within the next 6 months.
Measures
Structured Clinical Interview-Non-Patient Version for DSM-IV (SCID-N/P). The SCID-N/P First, Spitzer, Gibbon, & Williams, 1994 ) is a semistructured interview guide used to diagnose psychopathology. The interviews were administered by trained staff and supervised by independent doctoral-level psychologists. All interviews were audio-taped. Approximately 12.5% of interviews were randomly selected to verify accuracy of the diagnostic coding process; no discrepancies in diagnostic coding were noted.
Medical Screening Form (MSF). The MSF (Scheftner & Endicott, 1984 ) is a structured instrument administered by trained interviewers to assess lifetime medical history. This interview has excellent psychometric properties and has been extensively and successfully used in previous work for screening physical health problems and medication usage (e.g., Hays, Kallich, Mapes, Coons, & Carter, 1994) . In the present study, a composite variable was computed as an index of tobacco-related medical illnesses, which was used as a covariate in all models. Items in which participants indicated that they had ever been diagnosed (i.e., respiratory disease, asthma, heart problems, and hypertension, all coded 0 ϭ no, 1 ϭ yes) were summed to create a total score (observed range from 0 to 4), with greater scores reflecting the presence of multiple markers of tobacco-related medical illnesses. The medical history form has been used as an indicator of medical problems among cigarette smokers in other work (e.g., Brandt et al., 2015) .
Smoking History Questionnaire (SHQ). The SHQ (Brown, Lejuez, Kahler, & Strong, 2002 ) is a self-report questionnaire used to assess smoking history and pattern (e.g., smoking rate, age of onset of initiation). It has been successfully used in previous studies as a measure of smoking history (Zvolensky, Lejuez, Kahler, & Brown, 2004) . The present study used the following variables from the SHQ: average number of cigarettes smoked per day, age of onset of first cigarette, and age at onset of regular (daily) cigarette smoking.
Fagerström Test for Cigarette Dependence (FTCD). The FTCD (Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991 ) is a well-established 6-item scale designed to assess gradations in tobacco dependence. The measure exhibits good internal consistency reliability, high degree of test-retest reliability (Pomerleau, Carton, Lutzke, Flessland, & Pomerleau, 1994) , and positive relations with key smoking variables (e.g., salivary cotinine; Heatherton et al., 1991; Payne, Smith, McCracken, McSherry, & Antony, 1994) . This variable was used for descriptive purposes.
Carbon monoxide. Biochemical verification of smoking status was completed by carbon monoxide (CO) analysis of breath samples using a CMD/CO carbon monoxide monitor (Model 3110; Spirometrics, Inc.). Baseline level of CO and a time-varying variable representing the fluctuations in CO from quit day to Week 12 were used as covariates. This document is copyrighted by the American Psychological Association or one of its allied publishers.
Nicotine replacement therapy monitoring form. A researchergenerated form was employed to measure use of nicotine patch during the cessation period. This measure has been employed in past work to monitory nicotine replacement usage (Zvolensky et al., in press) . At the end of each quit week, participants responded to a question about whether they had used any nicotine replacement therapy during the past week.
Anxiety Sensitivity Index-III (ASI-III). The ASI-III (Taylor et al., 2007 ) is an 18-item self-report measure of the sensitivity to and fear of the potential negative consequences of anxiety-related symptoms and sensations. Respondents were asked to indicate on a 5-point Likert-type scale (0 ϭ very little to 4 ϭ very much) the degree to which they were concerned about each possible negative consequence. The ASI-III has been validated among smokers . In the present study, we evaluated the ASI-III at baseline and quit-day sessions (Cronbach's alpha ϭ .91 and .90, respectively). (Watson et al., 2007 ) is a 64-item self-report instrument that assesses distinct affect symptom dimensions within the past 2 weeks. Items are answered on a 5-point Likert scale ranging from not at all to extremely. The IDAS subscales show strong internal consistency, convergent and discriminant validity with psychiatric diagnoses and self-report measures (Watson et al., 2007) , and short-term retest reliability (r ϭ .79) with both community and psychiatric patient samples (Watson et al., 2007) . The IDAS has been successfully employed among smoking research (Mahaffey et al., 2016) . In the present study, we employed the 10-item Dysphoria Subscale (e.g., "I felt depressed") evaluated at baseline and quit-day sessions (Cronbach's alpha ϭ .89 and .91, respectively).
Inventory of Depression and Anxiety Symptoms-Dysphoria Subscale (IDAS). The IDAS
Minnesota Nicotine Withdrawal Scale (MNWS). The MNWS (Hughes & Hatsukami, 1998 ) was used to assess the experience of tobacco withdrawal symptoms over the last 24 hours. Utilizing a 5-point Likert-type scale (0 ϭ none to 4 ϭ severe), respondents rated the degree to which symptoms (including craving, irritability/frustration or anger, anxiety, difficulty concentrating, restlessness, increased appetite, depressed or sad mood, and insomnia) were experienced. The MNWS has shown good validity and reliability in previous studies (Allen, Hatsukami, Christianson, & Nelson, 1996; Hughes, Gust, Skoog, Keenan, & Fenwick, 1991) . Internal consistency for MNWS was good in the present sample (Cronbach's alphas ϭ .80, .82, .80, .80, and .81 for quit-day, Week 1, Week 2, Week 4, and Week 12 postquit, respectively).
Procedure
Data for the present study were collected during a multisite randomized controlled clinical trial examining the efficacy of two smoking cessation interventions described in detail elsewhere . Interested persons responding to community-based advertisements (e.g., flyers, newspaper ads, radio announcements) contacted the research team and were provided with a detailed description of the study via phone. Participants were then screened for initial eligibility, and if eligible, scheduled for a baseline appointment. At the baseline appointment, participants provided written informed consent, were interviewed using the SCID-I/NP, and completed a computerized self-report assessment battery as well as biochemical verification of smoking status to evaluate eligibility criteria.
Participants deemed eligible for the larger trial were randomly assigned to active or control treatment. The two treatment conditions included: a four-session cognitive-behavioral smoking cessation program with an added AS reduction component (active; i.e., Panic-Smoking Program), or a standard cognitive-behavioral smoking cessation program (control). Both treatments took place over four, 90-min sessions occurring once per week. The PanicSmoking Program (active) integrates interoceptive exposure, cognitive restructuring, and psychoeducation exercises developed for panic prevention and treatment programs with standard smoking cessation counseling. The Standard Cessation Program (control) includes only the smoking-related components of the PanicSmoking Program as well as a review of general health information not specific to anxiety or smoking (to equilibrate contact time across the two conditions). Both treatment groups received nicotine replacement therapy via the transdermal nicotine patch that was initiated at treatment Session 4 (quit day). Participants were offered the nicotine replacement therapy for up to 12 weeks postquit. Therapy sessions were supervised by principal investigators (MJZ and NBS) and checked for treatment fidelity by independent reviewers. Participants completed posttreatment assessment at 1, 2, 4, and 12 weeks postquit. Participants were compensated $12.50 for completing the baseline visit, an additional $25 if they completed all treatment sessions, and $15 for each follow-up assessment they completed. We did not exclude individuals who smoked during the postquit period from the current study because past work suggests excluding these individuals can create a potentially underrepresentative sample (Cook et al., 2015; Hughes, 2007) . The study protocol was approved by the Institutional Review Boards at the University of Vermont and Florida State University (clinicaltrials.gov NCT01753141).
Analytic Strategy
The present study examined the main and interactive effects of change in AS and dysphoria as predictors of change in postquit withdrawal symptoms over time assessed at quit day, 1, 2, 4, and 12 weeks postquit. Change in AS and dysphoria was calculated from baseline (preintervention) to quit day. Specifically, change for these predictors was derived using a two-step approach: (a) the difference score between quit day and baseline was computed, with a positive score indicating a greater reduction in AS and dysphoria and, (b) a residualized change score was derived by regressing the difference score on a baseline score. This residualized score was derived to represent a "pure" change score after variance associated with the baseline score was removed (Tucker, Damarin, & Messick, 1966) and was used in all following analyses. Tobacco withdrawal symptoms were modeled using data collected at quit day and over the postquit follow-up assessments (1, 2, 4, and 12 weeks postquit).
Five growth curve models were used to examine postquit change in withdrawal symptoms from quit day to postquit assessments. Data were analyzed using multilevel linear modeling (MLM) in PROC MIXED procedure in SAS 9.4 software (SAS, Inc., Cary, NC). The estimation of unknown parameters in the models was based on the restricted maximum-likelihood estimation. The models included two levels, where repeated assessments This document is copyrighted by the American Psychological Association or one of its allied publishers.
across time (Level 1; variables included time and time-varying breath CO) were nested within participants (Level 2; variables included change in AS, change in dysphoria, gender, baseline levels of CO, treatment condition, tobacco-related medical illness, and any use of nicotine replacement therapy). To allow for the time irregularity in the assessments, a time-structured predictor was included. Thus, the time values corresponded with the actual time spaces (in weeks) between each follow-up assessment (Singer & Willett, 2003) . A fully unconditional model (Model 1) was used to estimate the intraclass correlation and design effect (Muthén, & Satorra, 1995) . The magnitude of intraclass correlation and the size of the design effect (i.e., design effect ϭ 1ϩ [Average cluster size Ϫ1]
‫ء‬
Interclass correlation) were used to ensure that the growth curve models were the best data analytic approach in the context of the current study. Second, an unconditional linear growth model (Model 2) including examined quit-day levels (intercept) and a linear change in withdrawal symptoms (slopes) was used to examine whether change of withdrawal symptoms is adequately determined by a straight line. Third, an unconditional quadratic growth model (Model 3) was used to examine whether change of withdrawal symptoms is better determined by a curved line. Specifically, Model 3 examined quit-day levels (intercept) and both linear and quadratic changes in withdrawal symptoms (slopes). Fourth, a conditional model with Level 2 predictors (Model 4) was used to predict quit-day levels (intercept) and change in withdrawal symptoms (slopes) with change in dysphoria, change in AS, and their interaction.
A two-step process was used to fit Model 4: (a) the main-effects model, where predictors were simultaneously entered in the model and the main effects of each predictor were examined, and (b) the interactive-effects model, where the interaction terms of the two predictors were added into the main-effects model. Finally, a conditional model with Level 2 predictors and Level 2 covariates (Model 5) was used to examine whether individual characteristics from Model 4 significantly predict growth over and above the effects of covariates. Consistent with theoretical and empirical work, covariates included: gender , baseline levels of CO (Vogt, Selvin, & Billings, 1979) , treatment condition (Hooten et al., 2014) , tobacco-related medical illness (McLeish, Farris, Johnson, Bernstein, & Zvolensky, 2016) , use of nicotine replacement therapy (0 ϭ no use and 1 ϭ any use during the first 2 weeks following cessation; Silagy, Lancaster, Stead, Mant, & Fowler, 2004) , and time-varying breath CO (Hughes, 2007) . In all models, continuous variables were grand mean centered. Intercept and slopes in the models were considered as random to account for intraindividual variability of quit-day level and postquit change in withdrawal symptoms. Although the study was concerned with the fixed effects included in the models, the random effects were modeled to account for the variability of the observed effects across individuals (statistics not presented). The unstructured covariance matrix was used for the Random statement to allow for separate estimation of variances and covariances with no expected pattern (Raudenbush & Bryk, 2002) . The first-order autoregressive covariance matrix was used for the Repeated statement to allow for correlation among residuals as they were closer in time (i.e., the first assessments generally have higher correlations; Gibbons et al., 1993) . Satterthwaite approximation was used to calculate the degrees of freedom (Satterthwaite, 1946) .
Finally, using prototypical values (1 SD above and below mean of each predictor), we ran a post hoc slope analysis of Model 5. These analyses explored the interactive effects of change in dysphoria, change in AS on quit day (initial) status, and the rate of change in withdrawal symptoms over time using four prototypical subgroups (Raudenbush, Brennan, & Barnett, 1995; Singer & Willett, 2003) : (a) high AS reduction/high dysphoria reduction (1 SD above both means), (b) high AS reduction/limited dysphoria reduction (1 SD above and below mean respectively), (c) limited AS reduction/high dysphoria reduction (1 SD below and above means respectively), and (d) limited AS reduction/limited dysphoria reduction (1 SD below both means).
Results

Sample Descriptive Statistics
Of 529 smokers who were assigned to either the active or the control treatment, 265 completed the quit-day assessment and 198 (55.3% female; 86.8% Caucasian; M age ϭ 38.8, SD ϭ 14.0) completed at least one of the postquit follow-up assessment. Only those participants who completed at least one postquit follow-up assessment were included in the current analyses (active treatment: n ϭ 114; control treatment: n ϭ 84).
Participants reported smoking an average of 15.4 cigarettes per day (SD ϭ 7.4), smoking their first cigarette at 14.7 years of age (SD ϭ 3.6), and initiating regular (daily) smoking at 17.8 years of age (SD ϭ 3.9). The average level of baseline breath CO was 19.7 (SD ϭ 11.2) parts per million. The average score on the FTCD (Heatherton et al., 1991) was 4.9 (SD ϭ 2.2), indicating moderate levels of cigarette dependence. As determined by the baseline SCID-I/NP (First et al., 1994) , 31.4% of the sample met criteria for current (past year) Axis I psychopathology. The most common primary diagnoses included social anxiety disorder (10.0%), generalized anxiety disorder (5.7%), and major depressive disorder (4.1%).
Smoking and psychiatric characteristics of the sample, as well as all study variables are reported in Table 1 .
Growth Curve Models
Preliminary analyses. The intraclass correlation and the design effect for Model 1 were 0.56 and 2.8, respectively. Thus, about 56% of the total variance in withdrawal symptoms was due to interindividual differences and 44% was due to intraindividual differences. The magnitude of intraclass correlation and the size of the design effect indicated significant variability at both within and between individual levels, which supports the use of multilevel modeling.
Fixed effects. Table 2 presents the fixed effects of predictors for all models. For Model 2, the results suggested a significant linear decrease in mean withdrawal symptoms over time. For 1 We also examined the demographic characteristics of the current study participants compared to those that were not included in the analyses. Results indicated that there was no difference in terms of gender and smoking variables between the two groups. This document is copyrighted by the American Psychological Association or one of its allied publishers.
Model 3, the results suggested that the rate of growth decelerated over time as evinced by a significant negative quadratic term (Table 2 and Figure 1 ). For the main effects of Model 4, the results suggested that "higher" change scores (reduction) of AS and dysphoria predicted lower levels of quit-day withdrawal symptoms, but not of linear and quadratic trajectories of withdrawal symptoms.
For the interactive effects of Model 4, results suggested that the interaction term was a statistically significant predictor of the linear and quadratic trajectories of withdrawal symptoms across the 12-week postquit period, but not of quit-day withdrawal symptoms. Finally, after introducing the covariates in Model 5, the general pattern of the results remained consistent except for the quadratic trajectory, such that the interaction term became a marginally significant predictor (see Table 2 ).
Post hoc pairwise comparisons of differences between linear change in withdrawal symptoms showed a significant difference in slope for the high AS reduction/limited dysphoria reduction group compared with the limited AS reduction/limited dysphoria reduction group (see Table 3 ). No significant difference was found in the other pairwise comparisons. Inspection of the linear trajectories of the withdrawal symptom severity for the four prototypical groups revealed that the groups with higher levels of reduction in either AS or dysphoria (i.e., high AS reduction/high dysphoria reduction, high AS reduction/limited dysphoria reduction, and limited AS reduction/high dysphoria reduction) had lower levels of quit-day and Week 12 withdrawal symptoms compared with the limited AS reduction/ limited dysphoria reduction group (see Figure 2) . Moreover, the high AS reduction/limited dysphoria reduction group showed a fast reduction in their withdrawal symptoms, such that despite the higher initial levels, this group showed comparable levels of withdrawal symptoms at Week 12 compared with high AS reduction/high dysphoria reduction and limited AS reduction/ high dysphoria reduction groups (see Figure 2) . In other words, the linear trajectory of withdrawal symptoms appears to diverge across different degrees of AS reductions among "limited dysphoria reduction" (but not "high dysphoria reduction") groups.
Variance explained. The unexplained variability (residual variance) in withdrawal symptoms reduced from 8.5% in Model 1 Scheftner & Endicott, 1984) ; CO ϭ carbon monoxide; ASI-III ϭ Anxiety Sensitivity Index-III (Taylor et al., 2007) ; IDAS-DYS ϭ Inventory of Depression and Anxiety Symptoms-Dysphoria Subscale (Watson et al., 2007) ; Withdrawal symptoms as per the Minnesota Nicotine Withdrawal Scale (MNWS; Hughes & Hatsukami, 1998) . 1 We also examined the demographic characteristics of the current study participants compared to those that were not included in the analyses. Results indicated that there was no difference in terms of gender and smoking variables between the two groups. 2 The mean change in AS and dysphoria were 3.2 (SD ϭ 2.9) and 0.7 (SD ϭ 0.6), respectively. These scores were significantly correlated, r ϭ .38, p Ͻ .001. This document is copyrighted by the American Psychological Association or one of its allied publishers.
This article is intended solely for the personal use of the individual user and is not to be disseminated broadly. Note. N ϭ 198. Low CI and High CI ϭ 95% confidence interval of the estimated beta coefficient; Gender: 0 ϭ male and 1 ϭ female; CO ϭ carbon monoxide; NRT ϭ nicotine replacement therapy; CPD ϭ cigarettes per day; ⌬ Anxiety Sensitivity ϭ change in anxiety sensitivity (residualized change score); ⌬ Dysphoria ϭ change in dysphoria (residualized change score). 3 We reran analyses with psychopathology status as an additional covariate. The results did not change in terms of statistical significance or pattern of findings. We did not include psychopathology status as an additional covariate, as it is related to both the AS and dysphoria and tobacco withdrawal symptoms, and may therefore, risk over modeling the data (Miller & Chapman, 2001) . 4 We also reran all the models with the time-varying CO verified abstinence rate as the covariate. The pattern of the results stayed the same. 5 The active and control groups did not show significant differences in baseline, quit-day, or the rates of change in either AS or dysphoria. Furthermore, the "homogeneity of slopes" tests did not show significant interactions between treatment condition and either change in AS or dysphoria. This document is copyrighted by the American Psychological Association or one of its allied publishers.
to 7.5% in Model 2, suggesting that about 12.0% of the withinindividual variation in withdrawal symptoms was due to linear rate of change. This residual variance further changed from 7.5% in Model 2 to 7.4% in Model 3, suggesting that an additional 1.0% of the within-individual variation in withdrawal symptoms was due to the quadratic rate of change. Compared with Model 3, the unexplained variability substantially reduced in Model 4 from 7.4% to 5.8%, suggesting that the predictors accounted for 21.0% of the overall within-individual variability in withdrawal symptoms. Addition of covariates in Model 5 again reduced the unexplained variability to 5.5%, which suggests these covariates explain approximately 5.0% of the unexplained variance over and above the effects of the predictors in the model.
Discussion
As hypothesized, the interactive effects of change in AS and dysphoria were associated with linear change in postquit withdrawal symptoms. Specifically, the smokers that benefitted most from a reduction in AS were those that had lower levels of change in dysphoria. Thus, a reduction in dysphoric symptoms moderated the effects of reduction in AS in relation to linear change of withdrawal symptoms; see Figure 2 ). The observed moderating role of change in dysphoria is consistent with past research demonstrating the mitigating role of dysphoria for the effects of AS on smoking-related outcomes (Garey et al., 2016) , and extends it to dynamic models of AS and dysphoria. Specifically, the findings suggest smokers who do not experience a reduction in dysphoria following an intervention could benefit most from reducing AS. Notably, smokers who did not experience significant reductions in AS or dysphoria (i.e., limited AS reduction/limited dysphoria reduction) experienced the slowest reduction rate in tobacco withdrawal compared with the other three groups (see Figure 2) . These novel findings broadly highlight importance of better understanding the interplay of change in cognitive-affective vulnerability characteristics in terms of trajectories of tobacco withdrawal. It also suggests there is a need to assess and employ decision rules to identify and more effectively target the population of smokers with distinct cognitive-affective vulnerability profiles (Bierut, Johnson, & Saccone, 2014) .
Another clinically important finding was that change in AS and change in dysphoria each individually predicted quit-day withdrawal symptom severity. Specifically, smokers with greater decreases in either AS and/or dysphoria experienced less severe quit-day withdrawal symptoms. These observations are in line with past research which highlights the role of AS and dysphoria in terms of understanding the expression of tobacco withdrawal during acute periods of abstinence (Langdon et al., 2013; Zvolensky, Farris, Guillot et al., 2014) . Thus, regardless of any interactive effects, these data suggest that prequit reduction of AS and dysphoria could benefit smokers by reducing tobacco withdrawal (Zvolensky, Bogiaizian et al., 2014 Figure 2 . Differential linear change in withdrawal severity across four prototypical groups.
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Overall, the present findings suggest that addressing AS and dysphoria prior to engaging in a quit attempt may (a) lessen the intensity of withdrawal symptoms experienced on quit day; and (b) promote a faster decline in withdrawal symptom severity across the quit period. Given the strong association documented between withdrawal symptoms and smoking lapse/relapse (Piasecki et al., 2000) , prequit screening of AS and dysphoria followed by the delivery of the interventions that target these factors (i.e., with respect to the individual's specific vulnerability profile), should help decrease the severity of tobacco withdrawal, and by extension, improve cessation outcome.
There are several study limitations. First, our sample consisted of community-recruited, treatment-seeking daily cigarette smokers with moderate levels of cigarette dependence. Future studies may benefit by sampling from lighter and heavier smoking populations to determine the generalizability of the results to the general smoking population. Second, the study focused on AS and dysphoria. These constructs represent only two of many possible cognitive-affective characteristics that may be related to tobacco withdrawal. Future work could usefully continue to build multirisk factor models of withdrawal by incorporating other promising variables (e.g., distress intolerance, pain-related anxiety; . Third, the current study employed a composite withdrawal measure that amalgamates symptoms into a single index, including some symptoms which may not contribute to relapse risk (e.g., hunger, concentration problems; McCarthy, Piasecki, Fiore, & Baker, 2006; Piper et al., 2011) , and omitting other symptoms that do appear to reliably predict relapse (e.g., diminished positive affect; Piper et al., 2011; Strong et al., 2009) . It may therefore be useful for future research to explore the nature of specific withdrawal symptom clusters in the context of change in AS and dysphoria. Fourth, due to the focus of the one of the study arms on targeting AS, it is possible that some of the observed effects may be relatively more robust and not fully generalizable to the other smoking cessation treatments. Future work could therefore examine the present research questions within the context of other smoking cessation interventions. Fifth, the study design did not permit an examination of whether AS and dysphoria increased in anticipation of a quit attempt or were reactive responses to smoking cessation events. Future work using cross-lagged designs could help answer these types of questions. Similarly, the role of change in AS and/or dysphoria in affecting one's decision to make a quit attempt at a particular time could be examined in future research. Finally, no significant difference in prequit reduction in either AS or dysphoria were observed across the treatment groups. Although the two treatments may have improved mental health in general, future research could usefully explore how to target these constructs in a more efficient manner in the context of smoking cessation.
Together, the current data offer novel insight into the clinically important role of change in AS and dysphoria in relation to tobacco withdrawal. A key finding was that the benefits of a prequit reduction in AS in terms of the severity of withdrawal was most prominent for smokers with lower prequit reduction in dysphoria. Additionally, the findings indicated that reducing levels of AS and dysphoria prequit is broadly related to the degree of change in postquit withdrawal symptoms. Collectively, these data suggest there is apt to be clinical merit to employing strategies to address AS and/or dysphoria to more effectively manage emergent withdrawal symptoms following smoking cessation treatment. Future theory-driven work is needed to continue to understand the role of change in AS and dysphoria for withdrawal and other smoking processes (e.g., craving) and use such information to refine more personalized approaches to smoking cessation treatment.
